Stephen Levine, MD
Psychiatry · Beachwood, OHNPI 1659479038
Payments from drug & device makers
Across 230 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$839
- Otsuka America Pharmaceutical, Inc.$518
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$435
- AbbVie$336
- Alkermes, Inc.$330
- Takeda Pharmaceuticals U.S.A., Inc.$329
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,28097%
- Education$1313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 50 | $839 |
| Otsuka America Pharmaceutical, Inc. | 24 | $518 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $435 |
| AbbVie(2 entities) | 16 | $336 |
| Alkermes, Inc. | 14 | $330 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $329 |
| Axsome Therapeutics, Inc. | 10 | $252 |
| Corium, LLC | 8 | $207 |
| Sunovion Pharmaceuticals Inc. | 11 | $177 |
| Neos Therapeutics, LP | 17 | $161 |
| Johnson & Johnson | 6 | $138 |
| Vanda Pharmaceuticals Inc. | 4 | $123 |
| E.r. Squibb & Sons, L.L.C. | 6 | $116 |
| Neurocrine Biosciences, Inc. | 6 | $106 |
| AMAG Pharmaceuticals, Inc. | 2 | $82 |
| Tris Pharma Inc | 4 | $63 |
| Supernus Pharmaceuticals, Inc. | 3 | $59 |
| Bausch Health US, LLC | 2 | $34 |
| Shire North American Group Inc | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $12 |
How this compares
$4,411 in reported general payments places this provider in the 85th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 24 | $1,143 |
| Bupropion XlBupropion Hcl | 14 | $741 |
| Fluoxetine Hcl | 35 | $536 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $479 |
| Quetiapine Fumarate | 14 | $471 |
| Clonazepam | 14 | $364 |
| Escitalopram Oxalate | 13 | $364 |
| Lorazepam | 21 | $338 |
| Duloxetine Hcl | 21 | $299 |
| Trazodone Hcl | 24 | $268 |
| Alprazolam | 31 | $214 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Beachwood
- Amit MohanBeachwood$236K
- Boris RoyakBeachwood$62K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.